Related Experiment Videos
Azelnidipine (Sankyov KK).
1Rambaxy Laboratories Ltd, 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122 001, Haryana, India. jagmohank@ranbaxy.co.in
Idrugs : the Investigational Drugs Journal
|August 30, 2005
Summary
Azelnidipine, a novel calcium channel antagonist, effectively lowers blood pressure at rest and during exercise without impacting heart rate or cardiac output. This drug shows promise for hypertension treatment.
Area of Science:
- Cardiovascular pharmacology
- Clinical hypertension research
Background:
- Azelnidipine (CS-905) is an investigational, long-acting, once-daily oral calcium channel antagonist.
- It is under joint development by Sankyo and UBE for hypertension treatment.
Purpose of the Study:
- To evaluate the efficacy of azelnidipine in reducing blood pressure.
- To assess the effects of azelnidipine on cardiovascular parameters during rest and exercise.
Main Methods:
- A clinical trial was conducted and results presented at the European Meeting on Hypertension in 1995.
- The study involved assessing blood pressure, heart rate, and cardiac output at rest and during exercise.
Main Results:
- Azelnidipine demonstrated a significant decrease in both systolic and diastolic blood pressures.
- No significant alterations were observed in resting heart rate or cardiac output.
- Exercise-induced increases in heart rate and cardiac output remained unaffected.
Conclusions:
- Azelnidipine is an effective antihypertensive agent.
- Its mechanism of action does not adversely affect cardiac hemodynamics during rest or exercise.